Reproductive medicine is entering a decade in which clinical outcomes and software architecture become inseparable. The question facing clinic directors and lab managers is no longer whether to digitise, but how quickly the surrounding ecosystem of regulation, interoperability standards, and artificial intelligence will mature around them. The pace of that maturation will decide whether digital tools deliver on their promise of higher success rates and lower cost per live birth, or whether they remain a fragmented patchwork that adds administrative burden without clinical return.
The demand picture frames the opportunity, and in Europe it is well documented. The ESHRE European IVF Monitoring registry recorded over 1.1 million assisted-reproduction cycles across 37 European countries in 2021, a 20 percent rise on the pandemic-affected year before, and since 1997 it has logged almost 14 million treatments and 2.8 million births, making Europe the largest source of ART data in the world. That volume, together with rising infertility rates and later parenthood, points to sustained and growing demand for digital infrastructure. The software layer is growing with it: global IVF software estimates put compound annual growth at around 10 percent, and the narrower AI-powered embryo selection segment grows considerably faster, with Europe alone accounting for roughly 30 percent of that market and expanding at close to 18 percent a year. What remains uncertain is the quality and integration of that infrastructure, and that uncertainty is best understood through three scenarios.
What determines the outcome
Before the scenarios, it helps to name the variables that separate them. Three converging forces will shape the next ten years.
- Regulation
The first is regulation. In Europe, software that supports diagnosis or clinical decisions falls under the Medical Device Regulation (MDR), and any AI component now sits under the EU AI Act as well. Systems classified as MDR class IIa or higher that rely on AI are automatically treated as high-risk, creating a dual-compliance burden. The Digital Omnibus agreement has pushed the hardest deadlines outward: full obligations for AI built into regulated medical devices now apply from August 2028, while transparency requirements such as AI-content labelling arrive earlier, from August 2026. How cleanly these regimes are harmonised, and how consistently national authorities interpret them, will either accelerate or throttle innovation.
- Interoperability
The second is interoperability. The European Health Data Space (EHDS) entered into force in March 2025 and sets binding cross-border data-exchange deadlines for 2029 and 2031. FHIR is the technical backbone, and HL7 Europe published harmonised implementation guides in late 2025. Yet adoption is deeply uneven. Nordic and Benelux regions are well ahead, Southern Europe lags, and only a minority of European hospitals achieve full cross-border patient-data exchange today. Reproductive medicine, with its dense chain of laboratory instruments, registries, and patient touchpoints, is unusually exposed to this gap.
- Trust
The third is trust. AI in embryo assessment, gamete handling, and outcome prediction touches some of the most ethically charged decisions in medicine. Whether clinicians, patients, and the public come to trust these tools depends on clear guidelines, explainability, and demonstrable clinical validation. Trust is the multiplier that turns regulatory clarity and technical capability into actual adoption.
.png)
Best case: harmonised rules, connected systems, earned trust
In the optimistic scenario, the pieces align. Regulators deliver harmonised and clearly interpreted rules for software as a medical device and for AI, so that a tool cleared in one member state faces predictable, proportionate requirements across the others. The dual-compliance burden of MDR and the AI Act is streamlined through shared documentation and guidance, rather than duplicated audits, allowing vendors to move from validated prototype to market in months instead of years.
Interoperability becomes real rather than aspirational. FHIR-based exchange links clinics, laboratories, time-lapse incubators, witnessing systems, and patient apps into a coherent record. A patient moving between a referring gynaecologist, a fertility centre, and a specialist laboratory carries a continuous, structured history rather than a folder of PDFs and re-keyed data. Embryology data, hormonal monitoring, and treatment history flow into decision-support tools that surface genuinely personalised protocols.
On this foundation, AI-assisted diagnosis and embryo assessment win broad clinical acceptance because they are transparent, externally validated, and integrated into existing workflows rather than bolted on. Success rates improve measurably, cost per live birth falls, and the patient experience becomes coordinated and reassuring rather than fragmented and anxious. In this world the IVF software market grows at the upper end of, or beyond, current projections, with the AI segment compounding in the high teens. Vendors that can iterate quickly and evidence their claims capture disproportionate share, and clinics that adopted early enjoy a durable outcome advantage.
This scenario is plausible, but it assumes a level of regulatory coordination and cross-border technical execution that Europe has rarely achieved on schedule. It is the ceiling, not the expectation.
Base case: steady growth, incremental integration
The most likely path is continuous, unspectacular progress. The IVF software market grows in line with consensus forecasts, at a high single-digit to low double-digit annual rate depending on segment and geography, carried by rising infertility rates and the ongoing shift from paper and local databases to structured digital systems. Cloud deployment becomes the default for new installations, and clinics increasingly expect their core management platform to connect natively with laboratory instruments and registries.
AI enters through the side door, task by task, rather than as a wholesale transformation. Embryo-selection support, image analysis, and predictive scheduling gain traction where the clinical evidence is strongest and the regulatory path is clearest, while broader autonomous decision-making remains cautious and human-supervised. Adoption is real but measured, and clinics treat these tools as assistance rather than authority.
Interoperability improves gradually as FHIR implementation guides mature and EHDS deadlines approach, but progress is slowed by complex national transpositions, legacy laboratory systems, and the sheer diversity of instruments a fertility centre operates. Cross-border data exchange advances faster in the Nordic and Benelux markets and lags in the south, reproducing today’s uneven map for several more years. Compliance with MDR and evolving data-protection and AI rules remains a constant, resource-intensive, but manageable discipline. Innovation cycles are moderate: meaningful improvements arrive every year, but rarely the step-change the best case imagines.
For clinic decision-makers, this base case rewards deliberate strategy over heroics. The winners are not necessarily those who adopt the newest tool first, but those who choose platforms with credible interoperability roadmaps, a documented compliance posture, and the ability to absorb incremental AI capability without re-platforming. Vendor selection becomes a bet on which partners will still be investing, and still be compliant, in five years.
Worst case: fragmentation, cost, and eroded confidence
The pessimistic scenario is not dramatic collapse but slow, grinding friction. Regulatory adaptation for software and AI stays fragmented and slow, with national authorities interpreting the same rules differently and guidance arriving late. The dual burden of MDR and the AI Act, instead of being harmonised, becomes duplicated cost, and smaller vendors, who supply much of the specialised reproductive-medicine niche, struggle to carry it. Market uncertainty rises, product launches are delayed, and some promising tools never reach clinics at all.
Interoperability stalls. Absent enforced standardisation and with persistent data-protection anxiety, systems stay walled off from one another. Laboratory instruments, clinic platforms, registries, and patient apps continue to speak incompatible dialects, and the promise of a continuous patient record recedes. Clinics that invested in integration find their partners cannot reciprocate.
Meanwhile, ethical debate over AI in reproductive medicine intensifies without the anchor of clear, shared guidelines. High-profile disagreements about embryo-selection algorithms, opacity, or bias feed public mistrust. Clinicians, wary of liability and unconvinced by unexplained models, hold back. In this climate adoption stagnates, integrated functionality remains partial, and the market fragments into incompatible islands. Growth flattens or declines as clinics defer investment, waiting for a clarity that keeps not arriving.
The worst case is a reminder that the constraint on this market is rarely the technology itself. It is the connective tissue of rules, standards, and trust. When that tissue fails to form, capability sits unused.
What this means for clinic decision-makers
Across all three scenarios, the same strategic instincts hold up. Interoperability is the single highest-leverage criterion in any procurement decision, because a tool that cannot exchange structured data will lose value as EHDS obligations arrive regardless of how capable it is in isolation. FHIR readiness and a credible integration record should weigh at least as heavily as clinical features.
Regulatory posture is now part of due diligence, not a back-office afterthought. A vendor’s grasp of the MDR and AI Act interplay, and its transparency about how its AI components are classified and validated, signals whether it will still be sellable and supportable through 2028 and beyond. Ask how a tool is classified, what evidence supports it, and how the supplier plans to meet the August 2026 and August 2028 deadlines.
Finally, trust is built deliberately. AI tools that explain their reasoning, disclose their validation, and keep clinicians in control will be adopted; opaque ones will not, whatever their measured accuracy. Clinics that treat explainability and clinical evidence as requirements rather than nice-to-haves are effectively hedging against the worst case while positioning for the best.
The direction of travel is clear: reproductive medicine will be more digital, more data-driven, and more AI-assisted a decade from now. The open question is how much friction the ecosystem imposes along the way. That friction, more than any single technology, will determine whether the coming decade delivers meaningfully better outcomes for patients or merely more software.
Sources
ESHRE / European IVF Monitoring (EIM) Consortium, IVF and IUI treatment cycles increase across Europe (ESHRE 40th Annual Meeting, 2024): over 1.1 million ART cycles reported across 37 European countries in 2021 by 1,382 clinics (a 20 percent rise on 2020); almost 14 million treatments and 2.8 million births recorded since 1997. https://www.focusonreproduction.eu/press-releases/ivf-and-iui-treatment-cycles-increase-across-europe-along-with-stable-pregnancy-rates/
Precedence Research, AI-Powered Embryo Selection Market (report updated 13 April 2026): global market 320.00 million US dollars in 2025 rising to 1,747.16 million by 2035, CAGR 18.50 percent; Europe holds around 30 percent of the market with a 17.8 percent CAGR, Germany noted as a steady-growth market. https://www.precedenceresearch.com/ai-powered-embryo-selection-market
Verified Market Research, IVF Software Market (page updated 27 July 2025): global IVF software valued at 1.5 billion US dollars in 2023, rising to 4.2 billion by 2031, CAGR 10 percent. https://www.verifiedmarketresearch.com/product/ivf-software-market/
Patient Guard, The AI Act Omnibus Explained (15 June 2026): Digital Omnibus timeline, transparency obligations from August 2026, high-risk MDR/IVDR AI obligations extended to August 2028, “No Duplication” principle. https://patientguard.com/the-ai-act-omnibus-explained-what-the-2026-eu-rules-mean-for-medical-device-and-ivd-manufacturers/
European Union, Regulation (EU) 2024/1689 (Artificial Intelligence Act): primary legal text. https://eur-lex.europa.eu/eli/reg/2024/1689/oj
HL7 Europe, New FHIR Implementation Guides to support the EHDS (November 2025). https://hl7news.hl7.org/2026/01/02/new-hl7-europe-fhir-implementation-guides-to-support-the-european-health-data-space/
Firely, EHDS – European Health Data Space Regulation: EHDS in force March 2025, binding cross-border deadlines 2029 and 2031, FHIR as technical standard. https://fire.ly/ehds-european-health-data-space-regulation/
